Browse studies, page 1095
Page 1095 of 1,197, newest first. Search them all at once, ranked by relevance, in Evidence Hub.
- Effect of empagliflozin with or without carvedilol on tricuspid regurgitation and right ventricular remodeling: PROVE trial Journal of cardiovascular imaging, 2026
- Development and validation of a stability-indicating LC-MS/MS method for simultaneous estimation of empagliflozin and metoprolol in pharmaceutical dosage forms with forced degradation studies and computational assessment of degradation products The Analyst, 2026
- Urinary Frequency and Polydipsia Mimicking Diabetes Mellitus: Obesity-Related Secondary Focal Segmental Glomerulosclerosis with Concurrent Overactive Bladder — A Case Report 2026
- Tirzepatide Attenuates Diabetes-Associated Testicular Inflammation and Sperm DNA Fragmentation in Obese Diabetic Mice: Potential Pleiotropic Effects Beyond Glycemic Control 2026
- Personalized Knowledge-based Graph Neural Networks and Regression Analysis for Computational Diagnosis of High-Risk Cardiovascular Disease Patients 2026
- Copeptin Response to Empagliflozin in Patients with Recent Acute Coronary Syndrome and Newly Detected Dysglycaemia: a post-hoc analysis of the SOCOGAMI randomized controlled trial 2026
- On the clinical pharmacokinetics and pharmacodynamics and drug level informed optimization of SGLT2 inhibitors in patients with Type 2 Diabetes Mellitus 2026
- Real-World EHR Signals from a Cohort of Blinded Incretin Trial Participants Motivate Novel Indication Opportunities 2026
- Smoldering Multiple Myeloma in Glycogen Storage Disease Type Ib: Diagnostic Challenges e Short-Term Follow-Up with Empagliflozin 2026
- Sympathetic nervous system activity, tissue iron distribution, and their modulation by empagliflozin in the EMPATROPISM-FE trial Research Square, 2026
- Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo-controlled study Diabetes, obesity & metabolism, 2021
- The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease Diabetes, obesity & metabolism, 2022
- Empagliflozin improves vascular insulin sensitivity and muscle perfusion in persons with type 2 diabetes American journal of physiology. Endocrinology and metabolism, 2024
- Co-Loaded Nanoparticles of Empagliflozin and Rutin for Pancreatitis Prevention and Anticancer Activity Drug development research, 2025
- The effect of Empagliflozin on echocardiographic parameters in diabetic patients after acute myocardial infarction: A systematic review and meta-analysis with trial sequential analysis Irish journal of medical science, 2024
- SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart Cardiovascular diabetology, 2019
- Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition? The Journal of clinical endocrinology and metabolism, 2022
- Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors and the cardiovascular system Giornale italiano di cardiologia (2006), 2016
- The effects of empagliflozin on cardiometabolic risk factors in patients with type 2 diabetes: A short-term observational study Indian journal of pharmacology, 2021
- Correlation between myocardial strain and adverse remodeling in a non-diabetic model of heart failure following empagliflozin therapy Expert review of cardiovascular therapy, 2020
- Potential contribution of haemoconcentration to changes in lipid variables with empagliflozin in patients with type 2 diabetes: A post hoc analysis of pooled data from four phase 3 randomized clinical trials Diabetes, obesity & metabolism, 2021
- Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome Cardiovascular diabetology, 2016
- Distinct Mechanisms Responsible for the Increase in Glucose Production and Ketone Formation Caused by Empagliflozin in T2DM Patients Diabetes care, 2023
- Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers Diabetes, obesity & metabolism, 2013
- Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial? Molecular and cellular biochemistry, 2017
- Empagliflozin ameliorates olfactory bulbectomy-induced depression by mitigating oxidative stress and possible involvement of brain derived neurotrophic factor in diabetic rats The International journal of neuroscience, 2025
- Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME® trial Journal of diabetes investigation, 2019
- Impact of empagliflozin on blood pressure in dipper and non-dipper patients with type 2 diabetes mellitus and hypertension Diabetes, obesity & metabolism, 2017
- Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Single- and multiple-dose Once-daily Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Chinese Patients With Type 2 Diabetes Mellitus Clinical therapeutics, 2015
- The Effect of Empagliflozin on Renal Outcomes in Patients With Established Cardiovascular Disease: Systematic Review and Meta-Analysis of Randomised Placebo-Controlled Trials Endocrinology, diabetes & metabolism, 2026
- A potential novel treatment for cirrhosis-related ascites: Empagliflozin is safe and tolerable in advanced chronic liver disease British journal of clinical pharmacology, 2024
- The antioxidative effects of empagliflozin on high glucose‑induced epithelial-mesenchymal transition in peritoneal mesothelial cells via the Nrf2/HO-1 signaling Renal failure, 2022
- Low-Dose Empagliflozin Improves Systolic Heart Function after Myocardial Infarction in Rats: Regulation of MMP9, NHE1, and SERCA2a International journal of molecular sciences, 2021
- Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet BMJ open diabetes research & care, 2019
- Nonclinical safety of the sodium-glucose cotransporter 2 inhibitor empagliflozin International journal of toxicology, 2014
- Empagliflozin Disrupts a Tnfrsf12a-Mediated Feed Forward Loop That Promotes Left Ventricular Hypertrophy Cardiovascular drugs and therapy, 2022
- Empagliflozin attenuates liver fibrosis in high-fat diet/streptozotocin-induced mice by modulating gut microbiota Clinical and experimental pharmacology & physiology, 2024
- Empagliflozin attenuates neointimal hyperplasia after drug-eluting-stent implantation in patients with type 2 diabetes Heart and vessels, 2020
- Gliflozins slow down the progression of diabetic kidney disease Vnitrni lekarstvi, 2017
- Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and simvastatin following co-administration in healthy volunteers International journal of clinical pharmacology and therapeutics, 2014
- Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes Diabetes research and clinical practice, 2015
- Empagliflozin prohibits high-fructose diet-induced cardiac dysfunction in rats via attenuation of mitochondria-driven oxidative stress Life sciences, 2022
- Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: 3-year prospective observational study Diabetes research and clinical practice, 2021
- The Favorable Effect of Empagliflozin on Erectile Function in an Experimental Model of Type 2 Diabetes The journal of sexual medicine, 2018
- Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission Redox biology, 2018
- Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic Heart Failure: A Multimodality Study JACC. Cardiovascular imaging, 2021
- The impact of increased hepatic glucose production caused by empagliflozin on plasma glucose concentration in individuals with type 2 diabetes and nondiabetic individuals Diabetes, obesity & metabolism, 2024
- Pharmacokinetics and bioequivalence of a generic empagliflozin tablet versus a brand-named product and the food effects in healthy Chinese subjects Drug development and industrial pharmacy, 2020
- Budget Impact Analysis of Empagliflozin in the Treatment of Patients With Type 2 Diabetes With Established Cardiovascular Disease in South Africa Value in health regional issues, 2023
- Empagliflozin Attenuates Myocardial Sodium and Calcium Dysregulation and Reverses Cardiac Remodeling in Streptozotocin-Induced Diabetic Rats International journal of molecular sciences, 2019
- Protective effects of empagliflozin on testicular injury induced by torsion/detorsion in adult male rats Journal of pediatric urology, 2023
- Empagliflozin significantly prevents QTc prolongation due to amitriptyline intoxication Cardiovascular journal of Africa, 2023
- Liver tests, cardiovascular outcomes and effects of empagliflozin in patients with heart failure and preserved ejection fraction: The EMPEROR-Preserved trial European journal of heart failure, 2023
- The comparison of the antidiabetic effects of exenatide, empagliflozin, quercetin, and combination of the drugs in type 2 diabetic rats Fundamental & clinical pharmacology, 2024
- Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation European journal of heart failure, 2023
- The synergy of linagliptin and empagliflozin in catering to diabetes mellitus in Pakistan JPMA. The Journal of the Pakistan Medical Association, 2025
- Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy American journal of physiology. Renal physiology, 2019
- Renoprotective effects of empagliflozin are linked to activation of the tubuloglomerular feedback mechanism and blunting of the complement system American journal of physiology. Cell physiology, 2023
- Empagliflozin alleviates lipid deposition and inflammation in diabetic kidney disease by downregulating C1QC. Molecular and cellular biochemistry, 2026
- Sodium-Glucose Cotransporter-2 Inhibitor, Empagliflozin, Suppresses the Inflammatory Immune Response to Influenza Infection ImmunoHorizons, 2023
- Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure Journal of the American College of Cardiology, 2021
- Empagliflozin reduces diffuse myocardial fibrosis by extracellular volume mapping: A meta-analysis of clinical studies Frontiers in endocrinology, 2022
- Empagliflozin alone and in combination with metformin mitigates diabetes-associated renal complications Journal of medicine and life, 2024
- Comparing the effects of empagliflozin and liraglutide on lipid metabolism and intestinal microflora in diabetic mice PeerJ, 2024
- Effects of empagliflozin against indomethacin induced gastric mucosa Minerva endocrinology, 2023
- Evaluation of the effects of empagliflozin on acute lung injury in rat intestinal ischemia-reperfusion model Journal of endocrinological investigation, 2023
- Efficacy and safety of empagliflozin for the acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials Annals of medicine, 2025
- Empagliflozin alleviates hepatic ischemia-reperfusion injury by inhibiting c-Myc through the JAK1-STAT3 signaling pathway International immunopharmacology, 2025
- Clinical pharmacokinetics and pharmacodynamics of empagliflozin in patients with heart failure British journal of clinical pharmacology, 2024
- Empagliflozin and Dulaglutide are Effective against Obesity-induced Airway Hyperresponsiveness and Fibrosis in A Murine Model Scientific reports, 2019
- A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction The European journal of health economics : HEPAC : health economics in prevention and care, 2023
- Comparing and Contrasting the Effects of the SGLT Inhibitors Canagliflozin and Empagliflozin on the Progression of Retinopathy Frontiers in bioscience (Landmark edition), 2023
- Efficacy of empagliflozin as adjunctive therapy to citalopram in major depressive disorder: a randomized double-blind, placebo-controlled clinical trial BMC psychiatry, 2024
- Current understanding on pathogenesis and effective treatment of glycogen storage disease type Ib with empagliflozin: new insights coming from diabetes for its potential implications in other metabolic disorders Frontiers in endocrinology, 2023
- Empagliflozin Attenuates Cardiac Fibrosis by Suppressing Fibroblast-Mediated C-C Motif Chemokine Ligand 2 Expression Journal of the American Heart Association, 2026
- Empagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in routine care in East Asia: Results from the EMPRISE study Journal of diabetes investigation, 2023
- Repurposing empagliflozin in individuals with glycogen storage disease Ib: A value-based healthcare approach and systematic benefit-risk assessment Journal of inherited metabolic disease, 2024
- Efficacy and safety of empagliflozin at different doses in patients with type 2 diabetes mellitus: A network meta-analysis based on randomized controlled trials Journal of clinical pharmacy and therapeutics, 2022
- Cost-effectiveness of add-on empagliflozin versus standard of care in management of CKD in Malaysia, Thailand and Vietnam - findings from a modelling study assessing an EMPA-KIDNEY eligible population, using CKD progression model Journal of medical economics, 2024
- Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension Circulation, 2019
- Cost-effectiveness analysis of empagliflozin versus sitagliptin as second-line therapy for treatment in patients with type 2 diabetes in the United States Diabetes, obesity & metabolism, 2021
- Immediate and short-term outcomes of in-hospital canagliflozin initiation in acute heart failure: Results from the CANA-AHF randomized clinical trial Heart & lung : the journal of critical care, 2025
- Empagliflozin-mediated protection of heparan sulfate-rich endothelial glycocalyx during vascular inflammation Biochemical pharmacology, 2026
- Empagliflozin Improves Endothelial Function in an Ovariectomized Rat Model of Estrogen Deficiency Journal of cardiovascular translational research, 2026
- Long-Term Treatment with Empagliflozin Attenuates Renal Damage in Obese Zucker Rat Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2020
- Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus Clinical therapeutics, 2014
- Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication Hypertension (Dallas, Tex. : 1979), 2016
- Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation Cardiovascular research, 2021
- Impact of empagliflozin in patients with diabetes and heart failure Trends in cardiovascular medicine, 2017
- Improved inflammatory bowel disease, wound healing and normal oxidative burst under treatment with empagliflozin in glycogen storage disease type Ib Orphanet journal of rare diseases, 2020
- Effect of SGLT2 Inhibitor on Cardiomyopathy in a Rat Model of T2DM: Possible involvement of Cardiac Aquaporins Tissue & cell, 2023
- Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial The lancet. Diabetes & endocrinology, 2014
- SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in db/db Mice, a Model of Type 2 Diabetes International journal of molecular sciences, 2020
- Empagliflozin attenuates the renal tubular ferroptosis in diabetic kidney disease through AMPK/NRF2 pathway Free radical biology & medicine, 2023
- Empagliflozin improves serum uric acid and early cardiometabolic outcomes in asymptomatic hyperuricemia among patients with type 2 diabetes: A 6-month observational study Medicine, 2026
- Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin Current medical research and opinion, 2015
- Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials Diabetes, obesity & metabolism, 2016
- SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice EBioMedicine, 2017
- Empagliflozin reduces blood pressure and uric acid in patients with type 2 diabetes mellitus: a systematic review and meta-analysis Journal of human hypertension, 2019
- Urine Extracellular Vesicle miRNA Changes Induced by Vicadrostat with/Without Empagliflozin in Patients with Chronic Kidney Disease International journal of molecular sciences, 2025
